Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rituximab/yttrium Y 90 ibritumomab tiuxetan

Known as: IDEC-Y2B8/MOAB IDEC-C2B8 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
We are reporting on a 14-year-old boy with a very early relapse of pre-B acute lymphoblastic leukemia (ALL) and anaplastic… Expand
  • table 1
Is this relevant?
2005
2005
PurposeThe aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2001
2001
Mantle cell lymphoma (MCL) has a poor prognosis without cure; the median overall survival ranges only from 3 to 4 years… Expand
Is this relevant?
2001
2001
The chimeric monoclonal anti-CD20 antibody has been widely used for the treatment of relapsed or refractory low-grade B-cell non… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Rituximab (IDEC-C2B8, Mabthera(R)) is a chimeric (human-mouse) monoclonal antibody (MoAb) against the B-cell specific CD20… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Abstract.Dosimetry studies in patients with non-Hodgkin’s lymphoma were performed to estimate the radiation absorbed dose to… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1998
Highly Cited
1998
SummaryIn this report we present a patient with B-cell chronic lymphocytic leukemia who developed an acute tumor lysis syndrome… Expand
  • figure 1
Is this relevant?
Highly Cited
1998
Highly Cited
1998
BACKGROUND In clinical trials in the USA, IDEC-C2B8 (a mouse-human chimeric anti-CD20 monoclonal antibody) has demonstrated high… Expand
Is this relevant?
1998
1998
Treatment with IDEC‐C2B8 (C2B8), the chimeric anti‐CD20 antibody, was shown in a phase I‐II study to be very effective for the… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1997
Highly Cited
1997
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell-specific antigen CD20 expressed on non-Hodgkin's… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?